This was the email reply i recieved after i sent him a furious email.
Hi Jason
The Company's management has changed significantly over the past 12
months and so has the company's prospects. We have repaid all of our
convertible note debt US$20m), announced a US$165m licensing agreement
with Pfizer and recently raised US$18m in a placement to recapitalize
our funds so that we have at least 12 months cash. I can't explain the
continued fall in the share price other than I believe that we are
undervalued and that our price will recover. We are in good shape to
make a recovery.
PS: The 60 day cooling off period with Pfizer is ongoing. However, they
just increased their investment to US11.5m, it looks like a good
relationship to me, despite what the doubters say.
Regards
- Forums
- ASX - By Stock
- PSD
- for fcks sake
PSD
psivida limited
for fcks sake, page-21
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online